10 results
6-K
EX-99.2
PRFX
PainReform Ltd
15 May 24
Condensed Financial Statements
4:15pm
study of 15 patients undergoing a bunionectomy.
In May 2023, we announced that our supplier of active pharmaceutical ingredient, or API, received
6-K
EX-99.2
PRFX
PainReform Ltd
15 Nov 23
Condensed Financial Statements
4:09pm
supplier of the active pharmaceutical ingredient, or API, has received a deficiency notice from the FDA related to our supplier’s Drug Master File … part of our first Phase 3 trial is expected to commence once the required information has been provided by the supplier to the FDA and the deficiency
6-K
EX-99.1
PRFX
PainReform Ltd
15 Nov 23
Condensed Financial Statements
4:09pm
in thousands, except share and per share data
NOTE 1: GENERAL (Cont.)
In June 2023, the Company’s supplier of the API (active pharmaceutical ingredient … process and facility for the production of the API. As a result, the second part of Phase 3 trial was delayed. The supplier completed the review
6-K
EX-99.2
PRFX
PainReform Ltd
10 Aug 23
Current report (foreign)
4:18pm
trial of PRF-110 in patients undergoing bunionectomy surgery, we announced that our supplier of the API (active pharmaceutical ingredient) has received … information has been provided by the supplier to the FDA and the deficiency notice has been resolved. None of the issues raised relate to the Company’s PRF
6-K
EX-99.1
rqq4zl0i nsex9ad4
10 Aug 23
Current report (foreign)
4:18pm
6-K
EX-99.3
c9crdp73jwjf meal9
10 Aug 23
Current report (foreign)
4:18pm
6-K
EX-99.1
s3guwbx
7 Jun 23
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of
4:33pm
6-K
EX-99.2
pm5m 1d2qw
15 Aug 22
Current report (foreign)
6:16pm
- Prev
- 1
- Next